Group 1 - The stock price of Zai Lab Limited (02509) has increased by over 8%, reaching a high of 22.15 HKD, the highest since October of last year, with a nearly 40% increase in the past month [1] - As of the latest update, the stock is up 5.42%, trading at 21.4 HKD with a trading volume of 5.7078 million HKD [1] - Zai Lab is a biopharmaceutical company focused on therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] Group 2 - Zai Lab has a diverse product pipeline with multiple innovative candidates, including one approved product, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] - In April, Zai Lab signed a licensing agreement with Caldera Therapeutics for its clinical-stage long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement includes a one-time upfront payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD under specific conditions, along with tiered royalties on net sales [2] - Zai Lab's product Selinexor has entered the medical insurance directory, with projected sales of 300 million CNY in 2025 and peak sales estimated between 1.5 billion to 2 billion CNY, contributing to the company's revenue through profit-sharing [2]
港股异动 荃信生物-B(02509)盘中涨超8% 近一个月股价累涨近四成 自免双抗布局国内领先